BioBAT to Receive $50M From City’s Expanded LifeSci NYC Investment - Black Media Daily
*BioBAT to Receive $50M From City’s Expanded LifeSci NYC Investment! July 20, 2021 – Brooklyn, NY – New York City Economic Development Corporation (NYCEDC) announced a $50 million investment in life sciences at BioBAT to expand their lab space as part of the city’s LifeSci NYC initiative. NYCEDC and BioBAT officials toured the space that will receive funding to build new labs at BioBAT ...
RegenLabs Expands from Switzerland to BioBAT
A new anchor tenant has made its home at BioBAT. Expanding from Switzerland to Brooklyn, RegenLab USA, an international leader in regenerative medicine, is reaching a larger market in the U.S. location through their lab space at BioBAT.
RegenLab’s purpose and mission is driven by one word: medicine. As one of Europe's leaders in regenerative medicine, RegenLab’s innovations provide medical solutions for patients that can be used as alternatives for surgeries and provide aesthetic interventions. The team at RegenLab USA is excited to build and maintain their relationships with partners in the United States, where innovation is consistently supported through investments in research and technology.
New York and Brooklyn’s ability to foster innovation particularly stand out, and helped to bring RegenLabs to BioBAT. Currently, RegenLab has partnerships with SUNY Downstate and Maimonides Medical Center to facilitate and advance RegenLab’s research in passive immunization against COVID-19 through the transfer of antibodies in convalescent plasma.
February 2021
Pooled Surveillance Testing Program for Asymptomatic SARS-CoV-2 Infections in K-12 Schools and Universities
ABSTRACT: The negative impact of continued school closures during the height of the COVID-19 pandemic warrants the establishment of new cost-effective strategies for surveillance and screening to safely reopen and monitor for potential in-school transmission. Here, we present a novel approach to increase the availability of repetitive and routine Covid-19 testing that may ultimately reduce the overall viral burden in the community. We describe implementation of a testing program that included students, faculty and staff from K-12 schools and universities participating in the SalivaClear™ pooled surveillance method (Mirimus Clinical Labs, Brooklyn, NY). Over 400,000 saliva specimens were self-collected from students, faculty and staff from 93 K-12 schools and 18 universities and tested in pools of up to 24 samples over a 20-week period during this pandemic…
December 2020
Dr. Riley and Sr. Admin At SUNY Downstate Receive COVID Vaccine and Join Thousands of New Yorkers in Fight Against Pandemic
Dr. Wayne J. Riley, newly appointed as Board Chairman, received the COVID-19 vaccine on December 15 as a part of SUNY Downstate’s initiative to first administer the vaccine to essential frontline staff. People who work in emergency departments and intensive care units were some of the first to receive the vaccine.
November 2020
Brooklyn Borough President Eric L. Adams Awards $500k Grant To SUNY Downstate To Expand Biobat At the BAT
Brooklyn, NY – SUNY Downstate announced a recent $500K capital fund grant from Brooklyn Borough President Eric L. Adams to be used to construct state-of-the-art biotechnology research and manufacturing space at BioBAT. This grant will enable BioBAT to accommodate new companies that are either expanding from the regional incubators or would like to move to New York.
“Downstate is proud of the continued growth of BioBAT, and this grant will help more science and medical research firms grow in Brooklyn,” said SUNY Downstate President Wayne J. Riley, M.D…
November 2020
Congratulations to Dr. Wayne J. Riley, on his appointment as new Board Chairman of The New York Academy of Medicine
Congratulations to Dr. Wayne J. Riley, Chairman of BioBAT, Inc., for the historic appointment as Chairman of the New York Academy of Medicine. Dr. Riley M.D., MPH, MBA, MACP, has over 25 years of experience across medical, biotech, health care, executive level management, policy, and leadership roles. Dr. Riley serves as the President of SUNY Downstate Health Sciences University. His commitment to health and social equity has been demonstrated numerous times through his work as a prior member of NYAM’s Board of Trustees. Dr. Riley is also actively involved in projects to promote equity, such as the Action Agenda.
May 2020
Checking In With Algiknit
We touched base with Algiknit for a glimpse into their work toward developing biomaterials for fashion and apparel products that reduce waste, fight CO2 and microplastic pollution, and feed into a 21st Century economy. Algiknit is a biomaterials company combining science and design into textile production. Their team of designers and scientists are developing sustainable textile fiber, using kelp, to combat pollution and harmful waste in the fashion industry. They discuss the future of fabric sustainability and how BioBAT has supported the growth of their company. Read on to learn more about Algiknit and their mission toward changing the fashion ecosystem.
Aug. 13, 2020
NTN Buzztime, Inc. and Brooklyn ImmunoTherapeutics LLC Enter into Definitive Merger Agreement
CARLSBAD, Calif. and BROOKLYN, N.Y., Aug. 13, 2020 – NTN Buzztime, Inc. (NYSE American: NTN) and Brooklyn ImmunoTherapeutics LLC (“Brooklyn“), a privately-held biopharmaceutical company focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, today announced that the companies have entered into a definitive merger agreement. If approved by the stockholders of NTN Buzztime and the beneficial holders of the Class A membership interests of Brooklyn, Brooklyn will merge with a wholly-owned subsidiary of NTN Buzztime in an all-stock transaction. Following closing, which the parties expect will occur in the …